By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment firm Rodman & Renshaw has upgraded Sequenom's stock to "Market Perform" from "Market Underperform" following yesterday's publication by the San Diego-based firm of results on its non-invasive fetal trisomy 21 test.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.